利伐沙班疗效如何？

It is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets. So how effective is rivaroxaban?

Xarelto (rivaroxaban tablets) is a red film-coated tablet. Its main active ingredient is: Rivaroxaban, a highly selective oral drug that directly inhibits factor Xa. Clinically indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its main mechanism of action is: inhibitory factor Xa can interrupt the endogenous and exogenous pathways of the coagulation cascade and inhibit the generation of thrombin and thrombosis.

At the same time, the good efficacy of rivaroxaban is mainly because rivaroxaban is a highly selective oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets. A dose-dependent inhibition of factor Xa activity by rivaroxaban has been observed in humans. Clinical studies have shown that rivaroxaban can effectively prevent deep vein thrombosis after peri-hip fracture surgery. It has good safety and is worthy of clinical promotion.

Recently, a study published in the Journal of Thrombosis showed that monotherapy with the new oral anticoagulant rivaroxaban can effectively treat deep vein thrombosis and pulmonary embolism and prevent their subsequent recurrence in Chinese patients. The study randomly assigned Chinese patients to two groups: oral rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) or standard therapy (injectable enoxaparin bridged with a dose-adjusted vitamin K antagonist) for 3, 6, or 12 months. 

  The results showed that the two treatments were equally effective in treating acute symptomatic deep vein thrombosis and/or symptomatic pulmonary embolism, and the rivaroxaban group had a lower rate of major bleeding. In addition, the study found that rivaroxaban had similar efficacy in high-risk groups, such as elderly or frail patients, patients with kidney damage, cancer patients, and those with larger clots in the body. Furthermore, rivaroxaban was well tolerated by Chinese patients and did not require routine coagulation monitoring, dose adjustments, or dietary restrictions. 

The above is the treatment effect issue, I hope it can help everyone.